To maximize its prevention potential, the public health impact of pre-exposure prophylaxis (PrEP) requires an approach that will lead to: 1) large-scale adoption among eligible populations and 2) identification of current gaps among prescribers.
The prevention of HIV acquisition has been transformed over the last decade with the introduction of pre-exposure prophylaxis (PrEP), in which at-risk HIV uninfected individuals take antiretroviral medications daily to prevent infection.
Despite the commonly held belief that marijuana suppresses aggression, many cross-sectional and longitudinal surveys find positive associations between marijuana use and intimate partner violence (IPV).
In the last decade, the HIV prevention field has witnessed a distinct shift, with emphasis on biomedical strategies to supplement behavioral interventions. One of these approaches is the use of preexposure prophylaxis (PrEP), co-formulated antiretroviral medications taken to reduce the risk of HIV infection.